Eptinezumab Dosage

Medically reviewed by Drugs.com. Last updated on Mar 15, 2024.

Usual Adult Dose for Migraine Prophylaxis

Initial dose: 100 mg via IV infusion every 3 months
Maintenance dose: 100 mg or 300 mg via IV infusion every 3 months.

Comments:

• Some patients may benefit from the higher dose (300 mg every 3 months).
• See administration advice for infusion administration instructions.

Use: For the preventative treatment of migraine in adults

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

No adjustment recommended

Precautions

CONTRAINDICATIONS:

• Serious hypersensitivity to active substance or any product excipients; reactions have included anaphylaxis and angioedema.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• For IV infusion by a healthcare provider every 3 months.
• Infuse over approximately 30 minutes.
• Use an IV infusion set with a 0.2 or 0.22 micron in-line or add-on filter; once infusion is complete, flush line with 20 mL of sodium chloride 0.9%.
• Observe and monitor patients closely during administration for hypersensitivity or infusion-related reactions.

Storage requirements:

• Prior to use: Store refrigerated at 2C to 8C (36F to 46F) in the original carton to protect from light.
• Do not freeze or shake.
• Store diluted solution at room temperature between 20C to 25C (68F to 77F).

Reconstitution/preparation techniques:

• Product must be diluted prior to administration.
• Infusion bags should be made of polyvinyl chloride, polyethylene, or polyolefin.
• To dilute: Withdraw drug from vial(s) and inject into 100 mL bag of 0.9% sodium chloride; gently invert solution to mix, do not shake.
• Infuse solution within 8 hours of preparation.

IV compatibility:

• No other medications should be administered through infusion set or mixed with this drug.

Patient advice:

• Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
• Patients should be instructed to contact their healthcare provider if they experience signs or symptoms of an allergic reaction.
• Patients should be advised to speak with their healthcare provider if they become pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed during therapy.

Frequently asked questions

• What are the new drugs for the treatment of migraines?
• How is Vyepti different from Aimovig?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer